Salvage therapy for recurrent glioblastoma multiforme: a multimodal approach combining fluorescence-guided resurgery, interstitial irradiation, and chemotherapy

References

• Affronti ML, Heery CR, Herndon JE 2nd, Rich JN, Reardon DA, Desjardins A, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115:3501–11.
   PubMed Web of Science ®Google Scholar
• Archavlis E, Tselis N, Birn G, Ulrich P, Baltas D, Zamboglou N. Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: a retrospective cohort analysis of recurrent glioblastoma multiforme. BMJ Open. 2013;15;3(3):e002262.
   Web of Science ®Google Scholar
• Dirks P, Bernstein M, Muller PJ, Tucker WS. The value of reoperation for recurrent glioblastoma. Can J Surg. 1993;36:271–5.
   PubMed Web of Science ®Google Scholar
• Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28:3838–43.
   PubMed Web of Science ®Google Scholar
• Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma: Curr Treat Options Neurol. 2010;12:321–33.
   PubMed Web of Science ®Google Scholar
• Taal W, Segers-van Rijn JM, Kros JM, van Heuvel I, van der Rijt CC, Bromberg JE, et al. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol. 2012;108:195–200.
   PubMed Web of Science ®Google Scholar
• Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.
   PubMed Web of Science ®Google Scholar
• Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62:564–76.
   PubMed Web of Science ®Google Scholar
• Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg. 2012;117(6):1032–8.
   PubMed Web of Science ®Google Scholar
• Tykocki T, Michalik R, Bonicki W, Nauman P. Fluorescence-guided resection of primary and recurrent malignant gliomas with 5-aminolevulinic acid. Preliminary results. Neurol Neurochir Pol. 2012;46(1):47–51.
   PubMed Web of Science ®Google Scholar
• Brada M, Baumert B. Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Front Radiat Ther Oncol. 1999;33:241–3
   PubMedGoogle Scholar
• Tselis N, Kolotas C, Birn G, Röddiger S, Filipowicz I, Kontova M, et al. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol. 2007;183:563–70.
   PubMed Web of Science ®Google Scholar
• Kolotas C, Birn G, Baltas D, Rogge B, Ulrich P, Zamboglou N. CT guided interstitial high dose rate brachytherapy for recurrent malignant gliomas. Br J Radiol. 1999;72:805–8.
   PubMed Web of Science ®Google Scholar
• Chen J, Xu T. Recent therapeutic advances and insights of recurrent glioblastoma multiforme. Front Biosci (Landmark Ed). 2013;18:676–8.
   PubMed Web of Science ®Google Scholar
• Hart MG, Garside R, Rogers G. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2013;(4):CD007415.
   Google Scholar
• Wernicke AG, Sherr DL, Schwartz TH, Pannullo SC, Stieg PE, Boockvar JA, et al. The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study. Brachytherapy. 2010;9:91–9.
   PubMed Web of Science ®Google Scholar
• Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology. 2004;62:2113–5.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80.
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Hentschel B, Felsberg J, Schackert G, Simon M, Schnell O, et al. German Glioma Network. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer. 2012;131(6):1342–50.
   PubMed Web of Science ®Google Scholar
• Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15.
   PubMed Web of Science ®Google Scholar
• Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–42.
   PubMed Web of Science ®Google Scholar
• Feigl GC, Ritz R, Moraes M, Klein J, Ramina K, Gharabaghi A, et al. Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg. 2010;113(2):352–7.
   PubMed Web of Science ®Google Scholar
• Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol. 2010;97:382–6.
   PubMed Web of Science ®Google Scholar
• Bernstein M, Gutin PH. Interstitial irradiation of brain tumors: a review. Neurosurgery. 1981;9(6):741–50.
   PubMed Web of Science ®Google Scholar
• Arbit E, Shapiro JR, Fiola M, Malkin MG, Galicich JH. The significance of morphologically viable glioma cells found at the time of operation after interstitial brachytherapy. Neurosurgery. 1993;32(1):105–10.
   PubMed Web of Science ®Google Scholar
• Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys. 1992;24:583–91.
   PubMed Web of Science ®Google Scholar
• Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.
   PubMed Web of Science ®Google Scholar
• Shrieve DC, Alexander E 3rd, Wen PY, Fine HA, Kooy HM, Black PM, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery. 1995;36(2):275–82.
   PubMed Web of Science ®Google Scholar
• Trent S, Kong A, Short SC, Traish D, Ashley S, Dowe A, et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol. 2002;57:247–51.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131–8.
   PubMed Web of Science ®Google Scholar
• Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108(9):3749–54.
   PubMed Web of Science ®Google Scholar